Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China

This is a multicenter, non-interventional real-world study designed to assess the efficacy and safety of asciminib in patients with newly diagnosed CML.The study uses a prospective data collection design to gather baseline, pre- and post-treatment, and long-term follow-up data, enabling a comprehensive assessment of asciminib's clinical benefits.

NCT Number	NCT07375355
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Chronic Myeloid Leukemia in Chronic Phase
Enrollment	200 participants
Start Date	2026-02-12
Primary Completion	2028-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-01